Skip to main content
MedPathMedPath Home
Clinical Trials/JPRN-UMIN000017679
JPRN-UMIN000017679
Completed
Phase 2

Phase II study of hypofractionated proton beam therapy for localized prostate cancer - hypofractionated proton therapy for prostate cancer

Proton Medical Research Center, University of Tsukuba0 sites125 target enrollmentJune 1, 2015
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsProstate cancer

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Prostate cancer
Sponsor
Proton Medical Research Center, University of Tsukuba
Enrollment
125
Status
Completed
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 1, 2015
End Date
November 30, 2023
Last Updated
2 years ago
Study Type
Interventional
Sex
Male

Investigators

Sponsor
Proton Medical Research Center, University of Tsukuba

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • •Severe complications such as heart failure, and liver dysfunction other active malignant tumors history of pelvis irradiation not to allow discontinuing anticoagulant and antiplatelet therapy severe cognitive impairment

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
The phase II study of hypo-fractionated proton beam therapy for mucosal melanoma of the head and neck
JPRN-UMIN000001505ational Cancer Center Hospital East Division of Radiation Oncology35
Active, not recruiting
Phase 1
Hypofractionated Proton Beam Therapy for Localized Prostate CancerStage I Prostate Adenocarcinoma AJCC v7Stage II Prostate Adenocarcinoma AJCC v7
NCT01950351M.D. Anderson Cancer Center241
Not yet recruiting
Phase 2
Hypofractionated Proton Beam Therapy of 51.6Gy(RBE) in 12 fractions (3 weeks) with real-time-image gated spot-scanning system for non-metastatic prostate cancer (T1c-T4N0M0)Prostate cancer
JPRN-UMIN000046163Kyoto Prefectural University of Medicine Department of Radiology180
Active, not recruiting
Not Applicable
Phase II study of hypofractionated radio-chemotherapy with gemcitabine plus oxaliplatin for unresectable nonmetastatic locally advanced pancreatic cancer. - IRST 157.01
EUCTR2010-020379-22-ITISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI
Recruiting
Phase 2
Phase II non-randomized study on proton radiotherapy of thymic malignanciescancerThymoma10027655
NL-OMON51962Swedish Lung Cancer Study Group10